期刊
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
卷 106, 期 -, 页码 49-57出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neubiorev.2018.12.005
关键词
Fentanyl; Heroin; Illicit; Pharmacology; Beta-arrestin; Abuse; Efficacy; Subjective effects; Self-administration; Pain; Methadone; Naltrexone; Buprenorphine; Treatment
资金
- NIH NIDA [R01DA041781]
- DOD [W81XWH-15-1-0435]
- Shirley Stefan Hatos Foundation
- [U54DA037842]
- [R01DA039169]
- [R01DA035207]
Opioid overdoses, many of which are attributed to use of illicit fentanyl, are currently one of the leading causes of death in the U.S. Although fentanyl has been used safely for decades in clinical settings, the widespread use of illicit fentanyl is a recent phenomenon, Starting in 2013, illicitly manufactured fentanyl and its analogs began to appear on the streets. These substances were added to or sold as heroin, often unbeknownst to the user. Because fentanyl is so potent, only small amounts are needed to produce pharmacological effects, but the margin between safe and toxic doses is narrow. Surprisingly little is known about the exact signaling mechanisms underlying fentanyl-related respiratory depression or the effectiveness of naloxone in reversing this effect. Similarly, little is known about the ability of treatment medications such as buprenorphine, methadone, or naltrexone to reduce illicit fentanyl use. The present article reviews the receptor, preclinical and clinical pharmacology of fentanyl, and how its pharmacology may predict the effectiveness of currently approved medications for treating illicit fentanyl use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据